文献速递帕金森病与运动障碍认知障碍与痴呆

新发帕金森病APOE ε4携带者的临床、生物标志与功能连接特征

Clinical, Biological, and Functional Connectivity Profile of Patients With De Novo Parkinson Disease Who Are APOE ε4 Carriers.
PubMed 文献 · Neurology · 2025-12-05

单中心横断面研究纳入66例新诊断未用药帕金森病患者(14例APOE ε4携带者)与55名健康对照,比较临床评分、脑脊液淀粉样肽与高密度脑电功能连接。结果显示ε4携带者运动损害更重、脑脊液Aβ42/Aβ40降低,并存在α与β频段功能连接异常。

要点

  • APOE ε4携带的新发帕金森病患者运动损害更重,尤其是运动迟缓和步态障碍。
  • ε4携带者脑脊液Aβ42/Aβ40比值更低,提示早期淀粉样蛋白沉积。
  • ε4携带者α频段连接降低、β频段连接升高,α连接与步态和认知相关。

核心结论

  • APOE ε4定义了自起病即表现为更重运动损害、脑脊液Aβ42/Aβ40降低及独特功能连接异常的帕金森病亚型。
  • 早期淀粉样蛋白介导的网络破坏可能是ε4携带者的潜在生物学标志。
  • 研究支持将APOE ε4作为帕金森病早期诊断与治疗策略的分层标志物。

研究设计与样本

  • 单中心横断面研究,于意大利罗马Tor Vergata医院开展。
  • 纳入新诊断、未用药帕金森病患者66例(平均年龄63.2[10.1]岁,女性35%,ε4非携带者52例、携带者14例)及年龄性别匹配健康对照55名(平均年龄62.0[15.2]岁,女性42%)。
  • 患者按APOE基因型分为ε4与非ε4携带者,接受综合临床评估、脑脊液淀粉样肽与tau蛋白检测及高密度脑电功能连接分析。
  • 功能连接组间差异采用网络基础统计(network-based statistics)分析,临床与生物标志关联采用协方差分析与相关分析。

主要发现

  • PD ε4组较PD非ε4组运动损害更高,运动迟缓MDS-UPDRS part III评分为16.4[7.6] vs 11.0[5.6](p=0.02),步态障碍为3.46[2.23] vs 1.94[1.46](p=0.003)。
  • PD ε4组脑脊液Aβ42/Aβ40比值为0.09[0.03],低于非ε4组的0.13[0.03](p<0.001)。
  • 网络分析显示ε4相关功能连接改变:α频段连接降低(F=3.9,p=0.034),β频段连接升高(F=9.8,p<0.001)。
  • ε4携带者中α功能连接与步态障碍负相关(r=-0.62,p=0.02),与蒙特利尔认知评估正相关(r=0.57,p=0.03),与脑脊液Aβ42/Aβ40正相关(r=0.54,p=0.04)。
  • β功能连接与运动迟缓在两组均相关,ε4携带者相关性更强(r=0.54,p=0.04)而非ε4组为(r=0.28,p=0.04)。

临床怎么用

  • 对早期帕金森病患者可考虑APOE基因型分层,ε4携带者需更关注运动迟缓与步态损害。
  • ε4携带者可结合脑脊液Aβ42/Aβ40与脑电功能连接评估,辅助识别淀粉样蛋白相关网络破坏。
  • 该分层思路有望用于早期诊断与治疗策略的个体化选择。

局限性

  • 单中心研究,结果外推受限。
  • 横断面设计,无法确定因果关系与纵向演变。
  • ε4携带者样本量较小(14例)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Growing evidence suggests that the APOE ε4 allele, a genetic risk factor for Alzheimer disease (AD), influences the clinical-pathologic features of Parkinson disease (PD). APOE ε4 promotes brain amyloid accumulation, indicating a PD subtype more susceptible to late copathology. However, the early correlates of APOE ε4 carriers in PD are not known. In this study, we used a multimodal approach to define the clinical, neurochemical, and neurophysiologic profiles of APOE ε4 carriers in PD at onset. METHODS: We conducted a single-center, cross-sectional study at Tor Vergata Hospital (Rome, Italy), enrolling newly diagnosed, drug-naïve PD participants and age-matched/sex-matched healthy controls (HCs). Patients with PD were stratified by APOE genotype into ε4 and non-ε4 carriers and evaluated through a comprehensive clinical assessment and the measurement of CSF amyloid peptides and tau protein levels. Group differences in high-density EEG-based functional connectivity (FC) were analyzed using network-based statistics to identify APOE ε4-modulated patterns. Clinical and biomarker associations with network metrics were tested using analysis of covariance and correlation analyses. RESULTS: The study included 66 PD participants (mean age 63.2 [10.1] years, 35% female, 52 ε4 noncarriers, 14 ε4 carriers) and 55 HCs (mean age 62.0 [15.2] years, 42% female). PD ε4, compared with PD non-ε4, demonstrated higher motor impairment, especially in bradykinesia (16.4 [7.6] vs 11.0 [5.6], p = 0.02) and gait disturbances (3.46 [2.23] vs 1.94 [1.46], p = 0.003) Movement Disorder Society-sponsored Unified Parkinson's Disease Rating Scale part III scores, and reduced CSF amyloid-β42 (Aβ42)/amyloid-β40 (Aβ40) ratio (0.09 [0.03] vs 0.13 [0.03], p < 0.001). Network analyses identified ε4-related FC alterations: decreased α-band connectivity (F = 3.9, p = 0.034) and increased β-band connectivity (F = 9.8, p < 0.001). In ε4 carriers, α-FC correlated inversely with gait disturbances (r = -0.62, p = 0.02) and positively with Montreal Cognitive Assessment (r = 0.57, p = 0.03) and CSF Aβ42/Aβ40 (r = 0.54, p = 0.04). β-FC correlated with bradykinesia in both groups, with stronger associations in ε4 carriers (r = 0.54, p = 0.04) than in non-ε4 (r = 0.28, p = 0.04). DISCUSSION: APOE ε4 defines a PD subtype characterized by greater motor impairment, reduced CSF Aβ42/Aβ40, and distinct FC abnormalities since the onset. An early amyloid-mediated network disruption thus emerges as the potential biological signature of ε4 carriers. Although limited by single-center and cross-sectional design, this study supports APOE ε4 as a stratification marker for early diagnostic and therapeutic strategies in PD.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Conti M, Mascioli D, Simonetta C, et al. Clinical, Biological, and Functional Connectivity Profile of Patients With De Novo Parkinson Disease Who Are APOE ε4 Carriers. Neurology. 2025. PMID: 41348997. doi:10.1212/WNL.0000000000214449

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。